You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethapyrilene
Accession NumberDB04819
TypeSmall Molecule
GroupsWithdrawn
DescriptionMethapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. Manufacturers voluntarily withdrew methapyriline drug products from the market in May and June 1979.
Structure
Thumb
Synonyms
2-[[2-(Dimethylamino)ethyl]-2-thenylamino]pyridine
Methypyrilene
N,N-Dimethyl-N'-pyrid-2-yl-N'-2-thenylethylenediamine
Thenylpyramine
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Co-PyronilNot Available
HistadylNot Available
LullaminNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Methapyrilene Hydrochloride
135-23-9
Thumb
  • InChI Key: BONORRGKLJBGRV-UHFFFAOYSA-N
  • Monoisotopic Mass: 297.106646052
  • Average Mass: 297.847
DBSALT000334
Categories
UNIIA01LX40298
CAS number91-80-5
WeightAverage: 297.847
Monoisotopic: 297.106646052
Chemical FormulaC14H20ClN3S
InChI KeyInChIKey=BONORRGKLJBGRV-UHFFFAOYSA-N
InChI
InChI=1S/C14H19N3S.ClH/c1-16(2)9-10-17(12-13-6-5-11-18-13)14-7-3-4-8-15-14;/h3-8,11H,9-10,12H2,1-2H3;1H
IUPAC Name
N-[2-(dimethylamino)ethyl]-N-(thiophen-2-ylmethyl)pyridin-2-amine hydrochloride
SMILES
Cl.CN(C)CCN(CC1=CC=CS1)C1=CC=CC=N1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dialkylarylamines. These are aliphatic aromatic amines in which the amino group is linked to two aliphatic chains and one aromatic group.
KingdomOrganic compounds
Super ClassOrganonitrogen compounds
ClassAmines
Sub ClassTertiary amines
Direct ParentDialkylarylamines
Alternative Parents
Substituents
  • Dialkylarylamine
  • Aminopyridine
  • Imidolactam
  • Pyridine
  • Heteroaromatic compound
  • Thiophene
  • Tertiary aliphatic amine
  • Azacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Hydrochloride
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9873
Blood Brain Barrier+0.9492
Caco-2 permeable+0.6224
P-glycoprotein substrateSubstrate0.6832
P-glycoprotein inhibitor INon-inhibitor0.9755
P-glycoprotein inhibitor IINon-inhibitor0.9142
Renal organic cation transporterInhibitor0.5832
CYP450 2C9 substrateNon-substrate0.7548
CYP450 2D6 substrateNon-substrate0.7717
CYP450 3A4 substrateNon-substrate0.5307
CYP450 1A2 substrateInhibitor0.831
CYP450 2C9 inhibitorNon-inhibitor0.8932
CYP450 2D6 inhibitorInhibitor0.8168
CYP450 2C19 inhibitorNon-inhibitor0.7581
CYP450 3A4 inhibitorNon-inhibitor0.9942
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7722
Ames testNon AMES toxic0.888
CarcinogenicityNon-carcinogens0.9043
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5098 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.847
hERG inhibition (predictor II)Non-inhibitor0.6318
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
boiling point173-175 °C at 3.00E+00 mm HgNot Available
water solubility601 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP2.87SANGSTER (1994)
logS-2.64ADME Research, USCD
pKa8.85 (at 20 °C)PERRIN,DD (1965)
Predicted Properties
PropertyValueSource
logP3.11ChemAxon
pKa (Strongest Basic)8.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area19.37 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity78.16 m3·mol-1ChemAxon
Polarizability29.5 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesR06AC05
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Methapyrilene.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Methapyrilene.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Methapyrilene.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Methapyrilene.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Methapyrilene.
adipiplonThe risk or severity of adverse effects can be increased when Methapyrilene is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Methapyrilene.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Methapyrilene.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methapyrilene.
AmisulprideThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Methapyrilene.
AmoxapineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Amperozide.
AmphetamineAmphetamine may decrease the sedative activities of Methapyrilene.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methapyrilene.
ArticaineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Asenapine.
AzaperoneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Azaperone.
AzelastineMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Methapyrilene.
BaclofenThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Methapyrilene.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Methapyrilene.
BenzphetamineBenzphetamine may decrease the sedative activities of Methapyrilene.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Benzyl alcohol.
Benzylpenicilloyl PolylysineMethapyrilene may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Methapyrilene.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.
BrimonidineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methapyrilene.
BrompheniramineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methapyrilene.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Methapyrilene.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Methapyrilene.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methapyrilene.
ButacaineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Methapyrilene.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methapyrilene.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methapyrilene.
CarbinoxamineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Methapyrilene.
CarisoprodolThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Carisoprodol.
CetirizineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Methapyrilene.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methapyrilene.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Methapyrilene.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Methapyrilene.
ChlorphenamineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Chlorphenamine.
ChlorphentermineChlorphentermine may decrease the sedative activities of Methapyrilene.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methapyrilene.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methapyrilene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methapyrilene.
CitalopramThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Methapyrilene is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methapyrilene.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Methapyrilene.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Methapyrilene.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Methapyrilene.
CyclizineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methapyrilene.
CyproheptadineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methapyrilene.
DapoxetineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Methapyrilene.
DesipramineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methapyrilene.
DextroamphetamineDextroamphetamine may decrease the sedative activities of Methapyrilene.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Methapyrilene.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methapyrilene.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Methapyrilene.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Methapyrilene.
DifenoxinThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methapyrilene.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methapyrilene.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methapyrilene.
DimenhydrinateThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methapyrilene.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methapyrilene.
DoramectinThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.
DoxylamineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Methapyrilene is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Methapyrilene.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Methapyrilene.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methapyrilene.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Methapyrilene.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Methapyrilene.
EfavirenzThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Methapyrilene.
EntacaponeThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Entacapone.
EscitalopramThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Methapyrilene.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methapyrilene.
EthanolMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Methapyrilene.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methapyrilene.
EthosuximideThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Methapyrilene.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methapyrilene.
EtidocaineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Methapyrilene.
EtoperidoneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Methapyrilene.
EzogabineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Methapyrilene.
FenfluramineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methapyrilene.
FexofenadineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Methapyrilene.
FlunarizineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Methapyrilene.
FluoxetineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methapyrilene.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methapyrilene.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methapyrilene.
FluspirileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Fospropofol.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methapyrilene.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Methapyrilene is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Methapyrilene.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Methapyrilene.
GuanfacineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Methapyrilene.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methapyrilene.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Methapyrilene.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Methapyrilene.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Methapyrilene.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methapyrilene.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Methapyrilene.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methapyrilene.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Methapyrilene.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.
HydroxyzineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Indalpine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Methapyrilene.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Methapyrilene.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Methapyrilene.
KetobemidoneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Ketobemidone.
LamotrigineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Methapyrilene.
LevocabastineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methapyrilene.
LevomilnacipranThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methapyrilene.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Methapyrilene.
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Methapyrilene.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Methapyrilene.
LofentanilThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methapyrilene.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Methapyrilene.
Lu AA21004The risk or severity of adverse effects can be increased when Methapyrilene is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Methapyrilene.
MelperoneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Melperone.
MephentermineMephentermine may decrease the sedative activities of Methapyrilene.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methapyrilene.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methapyrilene.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methapyrilene.
MetaxaloneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Methapyrilene.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Methapyrilene.
MethamphetamineMethamphetamine may decrease the sedative activities of Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Methapyrilene.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Methapyrilene.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Methapyrilene.
MethsuximideThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methapyrilene.
MetyrosineMethapyrilene may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Methapyrilene.
MilnacipranThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.
MirtazapineMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Methapyrilene.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Methapyrilene.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Methapyrilene.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.
NabiloneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methapyrilene.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Methapyrilene.
Nitrous oxideThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methapyrilene.
OpiumThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Opium.
OrphenadrineMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Methapyrilene.
OsanetantThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methapyrilene.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methapyrilene.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Methapyrilene.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methapyrilene.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methapyrilene.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methapyrilene.
ParaldehydeMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Methapyrilene.
ParoxetineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methapyrilene.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methapyrilene.
PerampanelThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methapyrilene.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Methapyrilene.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methapyrilene.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Phenoxyethanol.
PhenterminePhentermine may decrease the sedative activities of Methapyrilene.
PhenytoinThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Methapyrilene.
PipamperoneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Pomalidomide.
PramipexoleMethapyrilene may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Methapyrilene.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methapyrilene.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Methapyrilene.
PrimidoneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Methapyrilene.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methapyrilene.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Methapyrilene.
PromethazineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methapyrilene.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Methapyrilene.
PropoxycaineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Methapyrilene is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Methapyrilene.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methapyrilene.
RamelteonThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Ramelteon.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methapyrilene.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methapyrilene.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methapyrilene.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methapyrilene.
RomifidineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Romifidine.
RopiniroleMethapyrilene may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methapyrilene.
RotigotineMethapyrilene may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Methapyrilene.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Methapyrilene.
ScopolamineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methapyrilene.
SertindoleThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methapyrilene.
Sodium oxybateThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Sodium oxybate.
StiripentolThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methapyrilene.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methapyrilene.
SuvorexantThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Methapyrilene.
TetrabenazineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tetrodotoxin.
ThalidomideMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Methapyrilene.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Methapyrilene.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Methapyrilene.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methapyrilene.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methapyrilene.
TiagabineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methapyrilene.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Methapyrilene.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methapyrilene.
TrazodoneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Methapyrilene.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methapyrilene.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methapyrilene.
TrimipramineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Methapyrilene.
VigabatrinThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methapyrilene.
ZiconotideThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methapyrilene.
ZolazepamThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Methapyrilene.
ZonisamideThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Methapyrilene.
ZotepineThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methapyrilene.
Food InteractionsNot Available
Comments
comments powered by Disqus
Drug created on September 11, 2007 14:19 / Updated on August 17, 2016 12:24